Transluminal Technologies, founded with a mission to innovate in the field of interventional cardiovascular medical devices, focuses on developing advanced solutions to improve patient outcomes post-surgery. Their flagship product, the velox CD™, is the world's first bioabsorbable magnesium alloy closure device designed to achieve immediate hemostasis and facilitate rapid patient recovery by sealing arteriotomies and naturally absorbing over time. The company primarily targets the cardiovascular surgery market, aiming to enhance the efficiency and safety of vascular closure procedures.

Notable affiliated individuals and investors include key figures in the medical device industry, although specific names are not publicly disclosed. Transluminal Technologies has achieved significant milestones, including the development and successful implementation of their innovative velox CD™ device. The impact of their technology is profound, offering a safer, faster, and more reliable method for vascular closure, which translates to improved recovery times and outcomes for patients undergoing cardiovascular surgeries.